Pyxis Oncology, Inc. Profile Avatar - Palmy Investing

Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targ…

Biotechnology
US, Cambridge [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Pyxis Oncology, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Pyxis Oncology, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Pyxis Oncology, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of PYXS's Analysis
CIK: 1782223 CUSIP: 747324101 ISIN: US7473241013 LEI: - UEI: -
Secondary Listings
PYXS has no secondary listings inside our databases.